The objective of the Chair for Interventional Immunology is to study the mechanisms utilized by the immune cells to control and eradicate malignant tumors, and to translate this knowledge into development of novel immunotherapeutic approaches for treatment of cancer, which can be tested in early clinical trials at RCI.

The main focus of our work is the characterization of the aspects of the effective and ineffective anti-tumor immune response mediated by T lymphocytes in the context of human cells and tissues.

Examples for the successful translation of our research into the clinic are:

• the adoptive transfer of tumor reactive bone marrow derived memory T cells 
  Shuetz et al, Cancer Immunol Immunother, 2009 
  Domschke et al, Cancer Immunol Immunother, 2013  
• the recruitment of tumor specific T cells in the tumor tissue mediated by low-dose irradiation
  Klug et al, Cancer Cell 2013 and 
• the identification of novel immune-checkpoint molecules utilizing high-throughput RNAi screening
  Khandelwal et al 2015 EMBO Mol Med.

The Chair of Interventional Immunology is working in close contact with the Medical Clinic III (Hematology/Oncology) at University Hospital Regensburg, which provides excellent conditions for patient-oriented immunological research and its translation into the clinic. Prof. Beckhove with his years of experience in the field, as well as in the education and guidance of students, has the right to be a scientific supervisor for doctoral students.

view program »